Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

MCLEAN, VA / ACCESS Newswire / July 31, 2025 / Gladstone Capital Corporation (Nasdaq:GLAD) announces the following event: ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

In a note to employees on Thursday, Moderna Inc. said it was laying off about 10% of its global workforce as part of the ...

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

Discover key takeaways from Moderna's Q2 2025 earnings call, including FDA approvals, cost reductions, pipeline strategies, and financial updates.

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine ...